期刊文献+

放化疗性口腔黏膜炎发生情况及危险因素的研究进展 被引量:21

Oral Mucositis Incidence and Risk Factors in Cancer Patients with Radiotherapy or Chemotherapy
下载PDF
导出
摘要 放化疗导致的口腔黏膜炎的发生率高、危害大,并严重影响患者的治疗、身心健康及生活质量。癌症放化疗性口腔黏膜炎会造成许多负面的和潜在的威胁生命安全的后遗症,尤其是头颈部肿瘤,目前尚无明确的药物预防策略建议。了解口腔黏膜炎的发生、发展情况及危险因素有利于医护人员采取有针对性的防护措施,以提高癌症患者的生活质量,减轻患者的经济负担。 Oral mucositis of chemoradiation with high incidence and serious hazardous, affects the cancer patient's quality of life, disease treatment, physical and psychological health. Chemoradiation relat- ed mucositis is associated with many negative and potentially life-threatening sequelae. Patients receiving chemoradiotherapy for head and neck cancers are at high risk for severe oral mucositis,however there are no definitive recommendations on pharmacologic preventive strategies. Medical staff's understanding of the emergence, progress and risk factors of oral mucositis is good for taking protective measures, improving the quality of life, and reducing the economic burden of the patients.
出处 《医学综述》 2013年第23期4315-4317,共3页 Medical Recapitulate
关键词 放射治疗 化学治疗 口腔黏膜炎 危险因素 Radiotherapy Chemotherapy Oral mucositis Risk factors
  • 相关文献

参考文献3

二级参考文献26

  • 1Ferlay J, Shin HR, Bray F, et a l. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. IntJ Cancer, 2010, 127(12): 2893-2917.
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2):92-98.
  • 3Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23 (11): 2513-2520.
  • 4Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-ceU lung cancer patients. Ann Oncol, 2005, 16(17): 1081-1086.
  • 5Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survial in gefitinib-treated chemorefractorylung adenocarcinomas. Clin Cancer Res,2005, 11 (16): 5878-5885.
  • 6Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
  • 7Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFIL N Engl J Med, 2010, 362(25): 2380-2388.
  • 8Mok TS, Wu YL, qqaongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N EngIJ Med, 2009, 361(10): 947-957.
  • 9Rafael Rosell, Enric Carcereny, Rad) Gervais, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012,13(3): 239-246.
  • 10Mitsudorni T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plusdocetaxel in patients with non-small-cell lung cancer harbouringmutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010j 11(2): 121-128.

共引文献48

同被引文献178

引证文献21

二级引证文献182

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部